Comparative Pharmacology
Head-to-head clinical analysis: A P L versus FOLLISTIM AQ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: A P L versus FOLLISTIM AQ.
A.P.L. vs FOLLISTIM AQ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
A.P.L. (Chorionic Gonadotropin) acts as a luteinizing hormone (LH) agonist, binding to LH receptors in the gonads to stimulate testosterone production in males and ovulation in females.
Recombinant human follicle-stimulating hormone (FSH) that binds to FSH receptors on granulosa cells in the ovary, stimulating follicular growth and maturation via activation of adenylyl cyclase and increased cAMP production.
500-1000 mg every 4-6 hours, not to exceed 3000 mg/day in adults.
75 to 300 IU subcutaneously once daily for 8 to 14 days, adjusted based on follicular response; maximum daily dose 450 IU and total duration not exceeding 14 days per cycle.
None Documented
None Documented
Terminal elimination half-life: 2.5–3.5 hours (elimination phase); clinical context: requires repeated dosing for sustained effect.
Terminal elimination half-life approximately 24-36 hours (subcutaneous route); clinical context supports daily dosing due to sustained follicular stimulation.
Renal: 10% unchanged; hepatic metabolism to inactive metabolites excreted in urine and feces (90% combined).
Primarily renal (90%), with intact follitropin alfa/beta and metabolites excreted in urine; biliary/fecal excretion minimal (<10%).
Category C
Category C
Gonadotropin
Gonadotropin